Modulation of CNS pain circuitry by intravenous and sublingual doses of buprenorphine

NeuroImage

Volumn 59, Issue 4, 2012, Pages 3762-3773

  Upadhyay, Jaymin ^a,b   Anderson, Julie ^a,b   Baumgartner, Richard ^a,c   Coimbra, Alexandre ^a,c   Schwarz, Adam J ^a,d   Pendse, Gautam ^a,b   Wallin, Diana ^a,b   Nutile, Lauren ^a,b   Bishop, James ^a,b   George, Edward ^a,b   Elman, Igor ^e   Sunkaraneni, Soujanya ^a,f   Maier, Gary ^a,f   Iyengar, Smriti ^a,d   Evelhoch, Jeffrey L ^a,c   Bleakman, David ^a,d   Hargreaves, Richard ^a,c   Becerra, Lino ^a,b,f   Borsook, David ^a,b,f  

^a Imaging Consortium for Drug Development   (United States)

^b MCLEAN HOSPITAL   (United States)

^c MERCK RESEARCH LABORATORIES   (United States)

^d ELI LILLY AND COMPANY   (United States)

^e VETERANS AFFAIRS MEDICAL CENTER   (United States)

^f Sunovion Inc   (United States)

Author keywords

Analgesia; Buprenorphine; Evoked pain fMRI; Functional connectivity; Putamen

Indexed keywords

BUPRENORPHINE; CYANOCOBALAMIN; PLACEBO; SODIUM CHLORIDE;

ADULT; AMYGDALOID NUCLEUS; ANALGESIC ACTIVITY; ARTICLE; BLOOD OXYGENATED LEVEL DEPENDENT RESPONSE; BRAIN FUNCTION; BRAIN REGION; BRAIN STEM; CEREBELLUM; CINGULATE GYRUS; COHORT ANALYSIS; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; EVOKED RESPONSE; FRONTAL CORTEX; FUNCTIONAL MAGNETIC RESONANCE IMAGING; GLOBUS PALLIDUS; HUMAN; HUMAN EXPERIMENT; HYPOTHALAMUS; INSULA; LIMBIC SYSTEM; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; PAIN; PARAHIPPOCAMPUS; PARIETAL CORTEX; POSTCENTRAL GYRUS; PRECUNEUS; PRIMARY MOTOR CORTEX; PRIMARY SOMATOSENSORY CORTEX; PRIORITY JOURNAL; PUTAMEN; RADIOLOGICAL PARAMETERS; RANDOMIZED CONTROLLED TRIAL; REST; SENSORIMOTOR FUNCTION; TEMPORAL CINGULUM; THALAMUS; TIME TO MAXIMUM PLASMA CONCENTRATION; VISUAL ANALOG SCALE;

ADMINISTRATION, SUBLINGUAL; ADULT; ANALGESICS, OPIOID; BRAIN; BUPRENORPHINE; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; HUMANS; INJECTIONS, INTRAVENOUS; MAGNETIC RESONANCE IMAGING; MALE; PAIN;

EID: 84855220752     PISSN: 10538119     EISSN: 10959572     Source Type: Journal    
DOI: 10.1016/j.neuroimage.2011.11.034     Document Type: Article

References (57)

1. Andrade A., Denome S., Jiang Y.Q., Marangoudakis S., Lipscombe D. Opioid inhibition of N-type Ca2+ channels and spinal analgesia couple to alternative splicing. Nat. Neurosci. 2010, 13:1249-1256.
2. Baliki M.N., Geha P.Y., Fields H.L., Apkarian A.V. Predicting value of pain and analgesia: nucleus accumbens response to noxious stimuli changes in the presence of chronic pain. Neuron 2010, 66:149-160.
3. Becerra L., Breiter H.C., Wise R., Gonzalez R.G., Borsook D. Reward circuitry activation by noxious thermal stimuli. Neuron 2001, 32:927-946.
4. Becerra L., Harter K., Gonzalez R.G., Borsook D. Functional magnetic resonance imaging measures of the effects of morphine on central nervous system circuitry in opioid-naive healthy volunteers. Anesth. Analg. 2006, 103:208-216.
5. Beckmann C.F., DeLuca M., Devlin J.T., Smith S.M. Investigations into resting-state connectivity using independent component analysis. Philos. Trans. R. Soc. Lond. B Biol. Sci. 2005, 360:1001-1013.
6. Behrens T.E., Johansen-Berg H., Woolrich M.W., Smith S.M., Wheeler-Kingshott C.A., Boulby P.A., Barker G.J., Sillery E.L., Sheehan K., Ciccarelli O., Thompson A.J., Brady J.M., Matthews P.M. Non-invasive mapping of connections between human thalamus and cortex using diffusion imaging. Nat. Neurosci. 2003, 6:750-757.
7. Bickel W.K., Amass L., Crean J.P., Badger G.J. Buprenorphine dosing every 1, 2, or 3 days in opioid-dependent patients. Psychopharmacology (Berl) 1999, 146:111-118.
8. Bingel U., Glascher J., Weiller C., Buchel C. Somatotopic representation of nociceptive information in the putamen: an event-related fMRI study. Cereb. Cortex 2004, 14:1340-1345.
9. Borsook D., Upadhyay J., Chudler E.H., Becerra L. A key role of the basal ganglia in pain and analgesia-insights gained through human functional imaging. Mol. Pain 2010, 6:27.
10. Chefer V.I., Denoroy L., Zapata A., Shippenberg T.S. Mu opioid receptor modulation of somatodendritic dopamine overflow: GABAergic and glutamatergic mechanisms. Eur. J. Neurosci. 2009, 30:272-278.
11. Chen J.I., Ha B., Bushnell M.C., Pike B., Duncan G.H. Differentiating noxious- and innocuous-related activation of human somatosensory cortices using temporal analysis of fMRI. J. Neurophysiol. 2002, 88:464-474.
12. Chudler E.H. Response properties of neurons in the caudate-putamen and globus pallidus to noxious and non-noxious thermal stimulation in anesthetized rats. Brain Res. 1998, 812:283-288.
13. Everitt B.J., Robins T.W. Neural systems of reinforcement for drug addiction: from actions to habits to compulsion. Nat. Neurosci. 2006, 8:1481-1489.
14. Greenwald M.K., Johanson C.E., Moody D.E., Woods J.H., Kilbourn M.R., Koeppe R.A., Schuster C.R., Zubieta J.K. Effects of buprenorphine maintenance dose on mu-opioid receptor availability, plasma concentrations, and antagonist blockade in heroin-dependent volunteers. Neuropsychopharmacology 2003, 28:2000-2009.
15. Guetti C., Angeletti C., Marinangeli F., Ciccozzi A., Baldascino G., Paladini A., Varrassi G. Transdermal buprenorphine for central neuropathic pain: clinical reports. Pain Pract. 2010, 11:446-452.
16. Hans G. Buprenorphine-a review of its role in neuropathic pain. J. Opioid Manag. 2007, 3:195-206.
17. Hawkinson J.E., Acosta-Burruel M., Espitia S.A. Opioid activity profiles indicate similarities between the nociceptin/orphanin FQ and opioid receptors. Eur. J. Pharmacol. 2000, 389:107-114.
18. Huang P., Kehner G.B., Cowan A., Liu-Chen L.Y. Comparison of pharmacological activities of buprenorphine and norbuprenorphine: norbuprenorphine is a potent opioid agonist. J. Pharmacol. Exp. Ther. 2001, 297:688-695.
19. Iannetti G.D., Zambreanu L., Cruccu G., Tracey I. Operculoinsular cortex encodes pain intensity at the earliest stages of cortical processing as indicated by amplitude of laser-evoked potentials in humans. Neuroscience 2005, 131:199-208.
20. Ide S., Minami M., Satoh M., Uhl G.R., Sora I., Ikeda K. Buprenorphine antinociception is abolished, but naloxone-sensitive reward is retained, in mu-opioid receptor knockout mice. Neuropsychopharmacology 2004, 29:1656-1663.
21. Jasinski D.R., Pevnick J.S., Griffith J.D. Human pharmacology and abuse potential of the analgesic buprenorphine: a potential agent for treating narcotic addiction. Arch. Gen. Psychiatry 1978, 35:501-516.
22. Johnson R.E., Fudala P.J., Payne R. Buprenorphine: considerations for pain management. J. Pain Symptom Manage. 2005, 29:297-326.
23. Khalili-Mahani, N., Zoethout, R.M., Beckmann, C.F., Baerends, E., de Kam, M.L., Soeter, R.P., Dahan, A., van Buchem, M.A., van Gerven, J.M., Rombouts, S.A., in Press. Effects of morphine and alcohol on functional brain connectivity during "resting state": A placebo-controlled crossover study in healthy young men. Hum. Brain. Mapp.
24. Leppa M., Korvenoja A., Carlson S., Timonen P., Martinkauppi S., Ahonen J., Rosenberg P.H., Aronen H.J., Kalso E. Acute opioid effects on human brain as revealed by functional magnetic resonance imaging. Neuroimage 2006, 31:661-669.
25. Ling W. Buprenorphine for opioid dependence. Expert Rev. Neurother. 2009, 9:609-616.
26. Lutfy K., Eitan S., Bryant C.D., Yang Y.C., Saliminejad N., Walwyn W., Kieffer B.L., Takeshima H., Carroll F.I., Maidment N.T., Evans C.J. Buprenorphine-induced antinociception is mediated by mu-opioid receptors and compromised by concomitant activation of opioid receptor-like receptors. J. Neurosci. 2003, 23:10331-10337.
27. Maihofner C., Baron R., DeCol R., Binder A., Birklein F., Deuschl G., Handwerker H.O., Schattschneider J. The motor system shows adaptive changes in complex regional pain syndrome. Brain 2007, 130:2671-2687.
28. Malinoff H.L., Barkin R.L., Wilson G. Sublingual buprenorphine is effective in the treatment of chronic pain syndrome. Am. J. Ther. 2005, 12:379-384.
29. Margolis E.B., Lock H., Chefer V.I., Shippenberg T.S., Hjelmstad G.O., Fields H.L. Kappa opioids selectively control dopaminergic neurons projecting to the prefrontal cortex. Proc. Natl. Acad. Sci. USA 2006, 103:2938-2942.
30. McAleer S.D., Mills R.J., Polack T., Hussain T., Rolan P.E., Gibbs A.D., Mullins F.G., Hussein Z. Pharmacokinetics of high-dose buprenorphine following single administration of sublingual tablet formulations in opioid naive healthy male volunteers under a naltrexone block. Drug Alcohol Depend. 2003, 72:75-83.
31. Mello N.K., Mendelson J.H., Lukas S.E., Gastfriend D.R., Teoh S.K., Holman B.L. Buprenorphine treatment of opiate and cocaine abuse: clinical and preclinical studies. Harv. Rev. Psychiatry 1993, 1:168-183.
32. Nakamura A., Yamada T., Goto A., Kato T., Ito K., Abe Y., Kachi T., Kakigi R. Somatosensory homunculus as drawn by MEG. Neuroimage 1998, 7:377-386.
33. Oertel B.G., Preibisch C., Wallenhorst T., Hummel T., Geisslinger G., Lanfermann H., Lotsch J. Differential opioid action on sensory and affective cerebral pain processing. Clin. Pharmacol. Ther. 2008, 83:577-588.
34. Olsen Y., Daumit G.L., Ford D.E. Opioid prescriptions by U.S. primary care physicians from 1992 to 2001. J. Pain 2006, 7:225-235.
35. Park I., Kim D., Song J., In C.H., Jeong S.W., Lee S.H., Min B., Lee D., Kim S.O. Buprederm, a new transdermal delivery system of buprenorphine: pharmacokinetic, efficacy and skin irritancy studies. Pharm. Res. 2008, 25:1052-1062.
36. Pendse G., Borsook D., Becerra L. Enhanced false discovery rate using Gaussian mixture models for thresholding fMRI statistical maps. Neuroimage 2009, 47:231-261.
37. Pergolizzi J.V., Mercadante S., Echaburu A.V., Van den Eynden B., Fragoso R.M., Mordarski S., Lybaert W., Beniak J., Oronska A., Slama O. The role of transdermal buprenorphine in the treatment of cancer pain: an expert panel consensus. Curr. Med. Res. Opin. 2009, 25:1517-1528.
38. Pergolizzi J., Aloisi A.M., Dahan A., Filitz J., Langford R., Likar R., Mercadante S., Morlion B., Raffa R.B., Sabatowski R., Sacerdote P., Torres L.M., Weinbroum A.A. Current knowledge of buprenorphine and its unique pharmacological profile. Pain Pract. 2010, 10:428-450.
39. Petry N.M., Bickel W.K., Badger G.J. A comparison of four buprenorphine dosing regimens in the treatment of opioid dependence. Clin. Pharmacol. Ther. 1999, 66:306-314.
40. Rothman R., Qi N.I., Xu H. Buprenorphine: Combating Drug Abuse with a Unique Opioid 1995, Wiley, New York.
41. Sadee W., Rosenbaum J.S., Herz A. Buprenorphine: differential interaction with opiate receptor subtypes in vivo. J. Pharmacol. Exp. Ther. 1982, 223:157-162.
42. Singer T., Seymour B., O'Doherty J., Kaube H., Dolan R.J., Frith C.D. Empathy for pain involves the affective but not sensory components of pain. Science 2004, 303:1157-1162.
43. Smith S.M., Nichols T.E. Threshold-free cluster enhancement: addressing problems of smoothing, threshold dependence and localisation in cluster inference. Neuroimage 2009, 44:83-98.
44. Starr C.J., Sawaki L., Wittenberg G.F., Burdette J.H., Oshiro Y., Quevedo A.S., Coghill R.C. Roles of the insular cortex in the modulation of pain: insights from brain lesions. J. Neurosci. 2009, 29:2684-2694.
45. Timmermann L., Ploner M., Haucke K., Schmitz F., Baltissen R., Schnitzler A. Differential coding of pain intensity in the human primary and secondary somatosensory cortex. J. Neurophysiol. 2001, 86:1499-1503.
46. Tzourio-Mazoyer N., Landeau B., Papathanassiou D., Crivello F., Etard O., Delcroix N., Mazoyer B., Joliot M. Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain. Neuroimage 2002, 15:273-289.
47. Upadhyay J., Pendse G., Anderson J., Schwarz A.J., Baumgartner R., Coimbra A., Bishop J., Knudsen J., George E., Grachev I., Iyengar S., Bleakman D., Hargreaves R., Borsook D., Becerra L. Improved characterization of BOLD responses for evoked sensory stimuli. Neuroimage 2010, 49:2275-2286.
48. Upadhyay J., Anderson J., Schwarz A.J., Coimbra A., Baumgartner R., Pendse G., George E., Nutile L., Wallin D., Bishop J., Neni S., Maier G., Robertson B., Iyenger S., Evelhoch J.L., Bleakman D., Hargreaves R., Becerra L., Borsook D. Imaging Drugs With and Without Clinical Analgesic Efficacy. Neuropsychopharmacology 2011, 36:2659-2673.
49. Vadivelu N., Anwar M. Buprenorphine in postoperative pain management. Anesthesiol. Clin. 2010, 28:601-609.
50. Wagner K.J., Sprenger T., Kochs E.F., Tölle T.R., Valet M., Willoch F. Imaging human cerebral pain modulation by dose-dependent opioid analgesia: a positron emission tomography activation study using remifentanil. Anesthesiology 2007, 106:548-556.
51. Wise R.G., Rogers R., Painter D., Bantick S., Ploghaus A., Williams P., Rapeport G., Tracey I. Combining fMRI with a pharmacokinetic model to determine which brain areas activated by painful stimulation are specifically modulated by remifentanil. Neuroimage 2002, 16:999-1014.
52. Wise R.G., Williams P., Tracey I. Using fMRI to quantify the time dependence of remifentanil analgesia in the human brain. Neuropsychopharmacology 2004, 29:626-635.
53. Wise R.G., Jolly A., Murphy K., Evans C.J., Hall J.E. Differential effects of opioid analgesics on functional connectivity of cortical-subcortical networks in humans. Proc. Int. Soc. Magn. Reson. Med. 2011, 19:434.
54. Woolrich M.W., Behrens T.E., Beckmann C.F., Jenkinson M., Smith S.M. Multilevel linear modelling for FMRI group analysis using Bayesian inference. Neuroimage 2004, 21:1732-1747.
55. Yassen A., Olofsen E., Romberg R., Sarton E., Danhof M., Dahan A. Mechanism-based pharmacokinetic-pharmacodynamic modeling of the antinociceptive effect of buprenorphine in healthy volunteers. Anesthesiology 2006, 104:1232-1242.
56. Zacny J.P., Conley K., Galinkin J. Comparing the subjective, psychomotor and physiological effects of intravenous buprenorphine and morphine in healthy volunteers. J. Pharmacol. Exp. Ther. 1997, 282:1187-1197.
57. Zubieta J., Greenwald M.K., Lombardi U., Woods J.H., Kilbourn M.R., Jewett D.M., Koeppe R.A., Schuster C.R., Johanson C.E. Buprenorphine-induced changes in mu-opioid receptor availability in male heroin-dependent volunteers: a preliminary study. Neuropsychopharmacology 2000, 23:326-334.